Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RCAN2-DT (RCAN2 divergent transcript) is annotated as a noncoding RNA gene (RNA gene), produced from the divergent transcription at the RCAN2 locus. Divergent transcripts are typically noncoding RNA species transcribed in the orientation opposite to a protein-coding gene's promoter, frequently with unclear function. There are no data to indicate that RCAN2-DT encodes a protein or is a validated target for drugs, nor is there evidence linking it directly to disease processes or biomarker status. Most research on the RCAN family pertains to the protein-coding gene RCAN2, which is involved in calcineurin regulation and has roles in cellular signaling, cilia function, and potentially disease; however, "RCAN2-DT" specifically refers to the noncoding transcript, not the protein[1][7][8]. Summary: RCAN2-DT is not a therapeutic or canonical protein target; it is a noncoding RNA gene with no established biomedical role. Information about the protein RCAN2 should not be conflated with RCAN2-DT.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RCAN2 divergent transcript (RCAN2-DT).